Expression of CXCR4, a chemokine receptor that plays a key role in tumor growth and tumor cell metastasis also its role has been described in a variety of tumors, is important in the diagnosis and treatment of cancers with this type of receptor. Overexpression of CXCR4 is important for overall survival without progression and provides a starting point for targeted therapies. CXCR4 is expressed in more than 30 types of cancer, such as metastatic breast, kidney, lung, brain, prostate, breast, pancreas, ovary and melanoma, etc. Also, it contributes to tumor growth, angiogenesis, metastasis and therapeutic resistance. Using PET / CT for diagnosis of cancers in which this type of receptor is expressed, can be helpful for choosing the best way of treatment.
The diagnostic radiopharmaceutical Ga-68-CIXAFOR, produced by labeling the PentixaFor peptide with gallium-68, intelligently detects CXCR4 receptors, and tumors in which this type of receptor is expressed can be detected using positron emission tomography (PET) method.